Cite
Haikala HM, Lopez T, Köhler J, et al. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd. Cancer Res. 2021;82(1):130-141doi: 10.1158/0008-5472.CAN-21-2426.
Haikala, H. M., Lopez, T., Köhler, J., Eser, P. O., Xu, M., Zeng, Q., Teceno, T. J., Ngo, K., Zhao, Y., Ivanova, E. V., Bertram, A. A., Leeper, B. A., Chambers, E. S., Adeni, A. E., Taus, L. J., Kuraguchi, M., Kirschmeier, P. T., Yu, C., Shiose, Y., Kamai, Y., Qiu, Y., Paweletz, C. P., Gokhale, P. C., & Jänne, P. A. (2022). EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd. Cancer research, 82(1), 130-141. https://doi.org/10.1158/0008-5472.CAN-21-2426
Haikala, Heidi M, et al. "EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd." Cancer research vol. 82,1 (2022): 130-141. doi: https://doi.org/10.1158/0008-5472.CAN-21-2426
Haikala HM, Lopez T, Köhler J, Eser PO, Xu M, Zeng Q, Teceno TJ, Ngo K, Zhao Y, Ivanova EV, Bertram AA, Leeper BA, Chambers ES, Adeni AE, Taus LJ, Kuraguchi M, Kirschmeier PT, Yu C, Shiose Y, Kamai Y, Qiu Y, Paweletz CP, Gokhale PC, Jänne PA. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd. Cancer Res. 2022 Jan 01;82(1):130-141. doi: 10.1158/0008-5472.CAN-21-2426. Epub 2021 Sep 21. PMID: 34548332; PMCID: PMC8732289.
Copy
Download .nbib